Cancer and cardiovascular diseases are the leading causes of premature death and cancer is likely to surpass cardiovascular diseases in most countries in the near future. The plethora of cancer subtypes and disease aetiologies impedes the development of efficient therapies. Standard treatment options include surgery, chemotherapy, and radiation therapy.
However, they often induce severe adverse effects. Furthermore, therapy-resistant malignant cells can expand, leading to relapse. Thus, the need for new treatment options is very high. Recently, versatile approaches have been investigated in the drug discovery process to develop more personalized and specific treatments. These include for example immunotherapies, like monoclonal antibodies and small-molecule drugs.
Characterizing the molecular interactions between drugs and their targets is mandatory to develop and improve these new treatment options. Moreover, molecular interactions have been shown to play a key role in cancer biology. For example, the interplay between cancer cells and the tumour microenvironment can support tumour growth and immune evasion.
Furthermore, the metastatic process is highly dependent on molecular interactions, for example during the remodelling of the extracellular matrix and the colonization of distant sites. Elucidating these interactions can reveal new pharmaceutical targets.
The switchSENSE® technology can be used to analyse molecular interactions in detail. It offers a flexible tool to enhance our understanding of tumour cells and cancer development as well as to optimize current treatment options and identify new therapeutic modalities.
→ Examine the effect of small molecule drugs on the genetic regulation in cancer cells (nucleic acid binders)
→ Characterize protein-protein interactions, for example the effect of a therapeutic compound on the conformation of target proteins/enzymes (conformational change analysis)
→ Investigate binding kinetics of new therapeutic tools like PROTACs
→ Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action
2021 I Nature Communications (open access)
→ Polymerase/DNA Interactions and Enzymatic Activity: Multiparameter Analysis with Electroswitchable Biosurfaces
2015 I Scientific Reports (open access)
→ Regulation of cadherin dimerization by chemical fragments as a trigger to inhibit cell adhesion
2021 I communications biology (open access)
→ Specific inhibition of splicing factor activity by decoy RNA oligonucleotides
2019 I Nature Communications (open access)
→ switchSENSE® Bispecific Antibodies
→ heliX® Biosensors I learn more
→ heliX® Chips I learn more
→ Reagents & Consumables I learn more
→ heliOS Software I learn more
→ proFIRE® conjugation I learn more
Discuss your specific needs with our specialists.